ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
78.50
-1.10 (-1.38%)
At close: Apr 28, 2026, 4:00 PM EDT
78.50
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:01 PM EDT
ANI Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for ANI Pharmaceuticals stock have an average target of 110, with a low estimate of 90 and a high estimate of 124. The average target predicts an increase of 40.13% from the current stock price of 78.50.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 16, 2026.
Analyst Ratings
The average analyst rating for ANI Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 3 | 3 | 3 | 2 |
| Buy | 2 | 3 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Maintains $115 → $124 | Strong Buy | Maintains | $115 → $124 | +57.96% | Jan 16, 2026 |
| Barclays | Barclays | Buy Initiates $100 | Buy | Initiates | $100 | +27.39% | Dec 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $114 → $115 | Strong Buy | Maintains | $114 → $115 | +46.50% | Nov 10, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $77 → $90 | Hold | Maintains | $77 → $90 | +14.65% | Oct 9, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $95 → $115 | Buy | Maintains | $95 → $115 | +46.50% | Sep 24, 2025 |
Financial Forecast
Revenue This Year
1.07B
from 883.37M
Increased by 21.01%
Revenue Next Year
1.26B
from 1.07B
Increased by 17.59%
EPS This Year
9.23
from 3.32
Increased by 177.79%
EPS Next Year
10.73
from 9.23
Increased by 16.19%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.2B | 1.4B | ||||||
| Avg | 1.1B | 1.3B | ||||||
| Low | 763.4M | 1.1B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 31.5% | 27.9% | ||||||
| Avg | 21.0% | 17.6% | ||||||
| Low | -13.6% | 4.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.77 | 12.40 | ||||||
| Avg | 9.23 | 10.73 | ||||||
| Low | 8.63 | 9.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 193.7% | 34.3% | ||||||
| Avg | 177.8% | 16.2% | ||||||
| Low | 159.7% | -1.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.